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ABSTRACT <H1> 
Over recent years there has been increasing interest in the role of neurostimulation in the 
treatment of headache disorders.  Currently both peripheral and central neuromodulation 
devices are available although evidence to support their use is still limited.  Both non-invasive 
and invasive devices can be used for neurostimulation. Non-invasive peripheral stimulation 
options include supra-orbital stimulation (Cefaly® device) and vagal nerve stimulation 
(gammaCore® device), while invasive peripheral stimulation options include occipital nerve 
stimulation and sphenopalatine ganglion stimulation. Non-invasive central neurostimulation 
option involves single pulse transcranial magnetic stimulation (SpringTMS® device), while 
invasive central neurostimulation can be carried out using ventral tegmental area deep brain 
stimulation.  Neurostimulation therapies offer a promising approach to otherwise medically 
intractable or difficult to treat headache disorders with each device having specific roles within 
the treatment pathway. 
INTRODUCTION <H1> 
Primary headache conditions are benign, reoccurring headaches not caused by any underlying 
structural issue or disease.  The primary headaches are subdivided into phenotypes based on 
the International Classification of Headache Disorders (ICHD-III beta).(1)  The main divisions 
are migraine and the trigeminal autonomic cephalalgias (TACs).  Migraine is a recurrent 
headache disorder manifesting in attacks of pain lasting between 4-72 hours, which is 
accompanied by nausea, vomiting, light and noise sensitivity and aggravation of the pain with 
movement.  The TACs are a group of disorders characterised by unilateral head pain occurring 
in association with prominent ipsilateral cranial autonomic features.  The TACs include cluster 
headache, paroxysmal hemicrania, hemicrania continua and short-lasting unilateral 
neuralgiform headache attacks, which is further subdivided into SUNCT (short-lasting 
unilateral neuralgiform headache attacks with conjunctival injection and tearing) and SUNA 
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(short-lasting unilateral neuralgiform headache attacks with autonomic symptoms).  The most 
common primary headache is migraine with an estimated 15% of the population affected.(2)  
The TACs are less common with estimated prevalence of cluster headache of 1 in 500 (3), of 
paroxysmal hemicrania around 0.5 per 1000 (4) and that of hemicrania continua and 
SUNCT/SUNA not well defined but thought to be similar to that of paroxysmal hemicrania.(4)  
The clinical features, epidemiology and first-line treatment options are summarised in Table 1.  
The above primary headache conditions can be classified by their frequency into either episodic 
or chronic forms.  Chronic migraine is defined as a headache occurring on 15 or more days of 
the month (of which eight or more are migrainous) for a period of over three months.  Chronic 
TACs are diagnosed when patients go a year without remission periods or with remission 
periods lasting less than one month.(1)  Chronic headache is a global health issue affecting up 
to 4% of the population, (5) with chronic migraine or cluster headache forming the majority of 
chronic headaches seen in neurology units.  The estimated prevalence of chronic migraine is 
2% and chronic cluster headache 0.02%.(6)  Patients may have headaches that are chronic from 
onset or evolve from an episodic form.   
Although advances in the management of headache disorders means that the majority can be 
managed with medical treatments, a significant minority will not tolerate or prove intractable 
to available preventative pharmacological treatments.  Neurostimulation techniques with 
peripheral and central targets appear to offer a promising approach to treating such patients.  
Devices allowing acute treatment of attacks may be useful to those unable to use or who 
overuse acute medications such as triptans.  The peripheral targets used include the occipital 
nerve, the supra-orbital nerves, the sphenopalatine ganglion and the vagus nerve.  Current 
central targets are the ventral tegmental area and the cortex.  In this chapter, the main focus is 
on the treatment of chronic migraine and chronic cluster headache as this is where the bulk of 
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literature and experience lies.  Some reference will be made to the treatment of episodic 
migraine and cluster headache where relevant. 
 PATHOPHYSIOLOGY OF PRIMARY HEADACHE CONDITIONS 
<H1> 
Migraine<H2> 
Migraine is a complex neurological disorder that affects multiple cortical, subcortical and 
brainstem regions that regulate the autonomic, affective, cognitive and sensory functions.  The 
pathophysiology of the condition involves different neural networks and pathways interacting 
together to generate the clinical features of migraine.  The main pathways and mechanisms 
involved in migraine generation include (Fig 1): 
 the trigeminovascular system including the large intracranial vessels,  
 brain hyperexcitability and cortical spreading depression (CSD),  
 the trigeminocervical complex consisting of the caudal trigeminal nucleus and the 
spinal roots of C1-C2.  
The innervation of large intracranial vessels and the dura comes from the first division of the 
trigeminal nerve, a pathway known as the trigeminovascular system.(7)  Activation of 
trigeminal nerve endings results in the release of neuro-inflammatory peptides such as 
calcitonin gene regulating peptide (CGRP), substance P and nitric oxide.  These inflammatory 
mediators result in the activation of trigeminal nerve endings on adjacent blood vessels and a 
positive feedback loop is established via trigeminal brainstem connections to higher centres 
resulting in pain generation. 
Trigeminal afferents pass caudally through the trigeminal ganglion to synapse in the 
trigeminal-cervical complex.  This complex provides an anatomical and functional overlap of 
trigeminal afferents and cervical afferents from the level of the trigeminal nucleus caudalis to 
the level of C2.(8)  Stimulation of the cervical neurones at this level results in activation of 
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trigeminal neurones, thus, nociceptive activation of either end of the pathway can result in both 
occipital and frontal pain.  The trigeminal nucleus also makes connections with the thalamus 
via brainstem nuclei such as the periaqueductal gray, dorsal raphe nucleus and locus coeruleus. 
 There is evidence to support the concept that migraine sufferers have a sustained state of brain 
hyper-excitability.(9)  Neurophysiological work shows increased visual evoked potentials and 
absence of habituation in migraineurs.  Genetic causes of migraine have been linked to 
mutations leading to increased levels of synaptic glutamate, an excitatory neurotransmitter and 
transcranial magnetic stimulation studies has suggested reduced phosphene thresholds in 
migraineurs compatible with hyper-excitability.  This excitability leads to a lowered threshold 
for the initiation of CSD.  Cortical spreading depression, the physiological substrate of aura, 
consist of a wave of neuronal excitation spreading across the cortex followed by a reciprocal 
wave of neuronal inhibition.(10)  Cortical spreading depression has been found to lead to the 
activation of the trigeminovascular system and potentially of brainstem regulatory centres, both 
of which can lead to pain generation. 
  
Trigeminal autonomic cephalalgias<H2> 
The pathophysiological constructs for TACs must account for the distinctive clinical 
characteristics of the disorders: the trigeminal distribution of pain, the ipsilateral autonomic 
features and the periodicity seen in cluster headache.  Pain innervation of the head comes from 
branches of the first division of the trigeminal nerve.  The links between the trigeminal system, 
the higher cervical nerve roots and brainstem structures are discussed above.  The ipsilateral 
autonomic features are thought to arise from cranial parasympathetic activation and 
sympathetic hypofunctioning.  The pathway controlling these symptoms is known as the 
trigeminoautonomic reflex. Experimental data suggests that stimulation of trigeminal afferents 
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results in cranial autonomic outflow via this reflex.(11)  In humans, the parasympathetic fibres 
involved in this reflex synapse in the sphenopalatine ganglion.  Although the 
trigeminoautonomic reflex is active in other headache syndromes, it is the degree of activation 
in TACs that give the distinctive clinical features.  Hypothalamic activation has been suggested 
on functional neuroimaging of TAC patients.(12-15)  There is evidence of the role of 
hypothalamus in mediating anti-nociceptive and autonomic responses when intracranial pain 
structures are activated.  In support of the role of the hypothalamus in pain processing in TACs, 
direct pathways between the hypothalamus and trigeminal nucleus have been mapped.  Other 
supporting data for the importance of the hypothalamus in attack generation or pain control in 
TACs are the periodicity of cluster headache attacks that would suggest involvement of 
suprachiasmatic nucleus of the hypothalamus, where the “body clock” is sited, and the fact that 
hypothalamic peptides Orexin A and B elicit both pro- and anti-nociceptive effects on the 
trigeminal system.(16) 
The current hypothesis is that TACs are due to a central abnormality in hypothalamic 
processing with subsequent activation of the trigeminovascular and trigeminoautonomic 
pathways via the superior salivatory nucleus, sphenopalatine ganglion and trigeminal 
pathways. 
 
PERIPHERAL NEUROSTIMULATION DEVICES<H1> 
Supraorbital nerve stimulation <H2> 
The trigeminal system has a crucial role in generation of head pain.  The supraorbital nerve is 
a branch of the frontal nerve (which in turn is a branch of the first division of the trigeminal 
nerve) and innervates the frontal sinus, upper eyelid and anterolateral part of the forehead and 
scalp.  A transcutaneous supraorbital nerve stimulator has been developed as a potential 
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treatment for headache and case reports also exist on the potential use of subcutaneous 
supraorbital nerve stimulation in isolation or alongside occipital nerve stimulator devices.  
Evidence for the use of transcutaneous supraorbital nerve stimulation <H3> 
Transcutaneous supraorbital nerve stimulation involves the use of an external device to deliver 
an electrical current through the supraorbital nerves.  The Cefaly® device is the only currently 
available external transcutaneous nerve stimulator.  It is battery powered and worn on the 
forehead using a headband-like device.  There is currently no evidence to support the use of 
transcutaneous nerve stimulation in chronic migraine or chronic cluster headache, either as an 
acute or preventative treatment.  Some limited evidence of its possible use in episodic migraine 
is available. 
Acute treatment of episodic migraine <H4>  
No controlled evidence for the use of transcutaneous supraorbital nerve stimulation in the acute 
treatment of episodic migraine has been published.  However, a single pilot study of the 
Cefaly® device, reported that use of the device was associated with pain freedom in only 13% 
of treated cases and actually had no effect in 57% of attacks.(17) 
Preventative treatment of episodic migraine <H4> 
The evidence for transcutaneous supraorbital nerve stimulation in preventative treatment of 
episodic migraine comes from a small sham-controlled study of the Cefaly® device and 
manufacturer’s post-marketing survey data.(18, 19)  The sham-controlled study of 67 patients 
with episodic migraine using either a sham or active supraorbital nerve stimulator device for 
three months reported a significant drop of 30% in migraine days in the active group compared 
to 4.9% in the sham group.(18)  Responder rates for the device were comparable to traditional 
migraine preventative agents such as propranolol.(20)  The post-marketing survey incorporated 
data from 2313 subjects who used the transcutaneous supraorbital nerve stimulator for migraine 
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prevention.  Fifty three percent of subjects rated themselves “satisfied” and continued treatment 
after a 40-day trial period.(19)  Although the therapeutic gain in migraine day reduction was 
lower at 12% than that seen in other migraine preventatives such as topiramate (25%), the 
lower levels of adverse events and higher rates of patient satisfaction with Cefaly® device may 
counterbalance this issue.  
Evidence for the use of subcutaneous supraorbital nerve stimulation <H3> 
Subcutaneous supraorbital nerve stimulation is achieved by placing subdermal-subcutaenous 
electrodes on the forehead in the territory innervated by the supraorbital nerve.(21)  The 
electrodes can be placed in isolation or in combination with occipital nerve electrodes.  The 
only evidence for the use of subcutaneous supraorbital nerve stimulation comes from small 
open-label case series on the preventative treatment of chronic migraine and chronic cluster 
headache, most often in combination with occipital electrodes.     
Preventative treatment of chronic migraine <H4>  
Two small series are available in the literature on the use of combined supraorbital and occipital 
nerve stimulation for the prevention of intractable chronic migraine.  The first was by Reed et 
al. (22) and included seven patients receiving bilateral supraorbital and occipital electrodes.  
With a median follow-up of 15 months, all patients reported a more than 50% reduction in 
headache severity.  Adverse events included lead migration, infection and allergy.  Hann and 
Sharan performed a similar procedure on 14 patients.(23)  With a mean follow-up of 31 months, 
ten patients had a more than 50% reduction in headache severity.  Adverse events included 
lead migration, allodynia and infection and the group reported a reoperation rate of 36%.   
Preventative treatment of chronic cluster headache <H4>  
Current literature on subcutaneous supraorbital nerve stimulation for chronic cluster headache 
is limited to a total of six patients, one case report and one case series.  Narouze and Kapural 
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were the first to publish a case report of isolated supraorbital nerve stimulation for chronic 
cluster headache in 2007.(24) Following the implant of a unilateral lead with programmes for 
both preventative and acute treatments, the patient had a complete remission of pain for over 
14 months.  When the stimulation was terminated, the attacks returned within 24 hours.  
Interestingly, the device was also successfully used as an abortive treatment to terminate acute 
attacks.  The second series of four chronic cluster headache patients with a mixture of unilateral 
and bilateral leads reported a more than 50% reduction in pain severity in all patients after a 
follow-up of 25 months.(25)  Adverse events were high with two patients suffering electrode 
erosion through the skin and one a lead infection. 
Safety of supraorbital nerve stimulation <H3> 
Transcutaneous supraorbital nerve stimulation appears to be a safe and well-tolerated treatment 
option.  In the study from Magis et al. of 2313 participants using the Cefaly® device for the 
treatment of migraine only 4% of subjects reported any adverse events.(19)  The most frequent 
adverse event was intolerable paraesthesia (30% of adverse events) but sleepiness during 
treatment (12%), skin irritation at the application site (5%) and worsening of headache with 
treatment (12%) were also reported. 
Subcutaneous supraorbital nerve stimulation seems to have a similar risk profile to ONS. As 
the majority of patients reported in literature had both ONS and supraorbital electrodes, the 
adverse event data is discussed in ONS section. 
The possible role of supraorbital nerve stimulation<H3> (Table 2) 
Transcutaneous supraorbital stimulation may be useful in the prevention of episodic migraine 
in those unable to tolerate or not responding to traditional pharmacotherapy.  As yet, there is 
not enough evidence to support its use for chronic migraine, chronic cluster headache or acute 
treatment of either migrainous or cluster attacks. From the limited evidence available for 
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invasive supraorbital nerve stimulation, routine use of this procedure to treatment primary 
headaches cannot be advocated as yet  
Vagal nerve stimulation <H2> 
The vagus nerve contains both motor and sensory components and has a role in controlling 
autonomic responses as well as pain processing via its projections to higher pain control 
centres.  The initial concept of vagal nerve stimulation as a headache treatment came following 
observations of migraine improvement in patients undergoing invasive vagal nerve stimulator 
implants for intractable epilepsy.(26)  The use of invasive vagal nerve stimulation for headache 
has been limited to small case reports.  The development of non-invasive transcutaneous vagal 
nerve stimulator devices such as the gammaCore®, a handheld device used on the neck, has 
led to a resurgence of interest in the role of vagal nerve modulation in primary headache. 
Evidence for the use of transcutaneous vagal nerve stimulation <H3> 
Preventative treatment of chronic cluster headache<H4> 
Available evidence for the possible use of transcutaneous vagal nerve stimulation comes from 
a study of the gammaCore® device, the Prevention and Acute Treatment of Chronic Cluster 
Headache (PREVA) trial.(27)  This trial, consisting of 45 active and 47 control subjects, 
compared standard of care plus vagal nerve stimulation to standard care alone.  Regular use of 
the gammaCore® device for four weeks was associated with a significant reduction in cluster 
attack frequency compared to control (6 vs. 2 less attacks a week).  The 50% response rate was 
also higher in the active group (40% vs. 8%).  Following a four-week extension phase, both 
the reduction in attack frequency and response rate were seen to increase (to 8 attacks a week 
less and a 46% responder rate) suggesting a prolonged period of use is required to gain maximal 
benefit.  Following treatment, 50% reported satisfaction with the device and 65% would 
recommend treatment to others. 
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Acute treatment of chronic cluster headache<H4> 
A small open-label series of 19 patients using the gammaCore® device reported that it was 
useful as an acute treatment with 47% of attacks terminated within 11 minutes.(28) 
Subsequently, the PREVA study also reported on the use of the gammaCore® device to abort 
cluster attacks.(27)  The use of transcutaneous vagal nerve stimulation as an acute treatment in 
75 of 92 participants had no effect on cluster headache attack duration or severity.  The PREVA 
study results suggest that there is no role for the use of gammaCore® as an acute treatment in 
cluster headache. 
Preventative treatment of chronic migraine<H4> 
The controlled trial evidence for the use of transcutaneous vagal nerve stimulation with the  
gammaCore® as a preventative treatment in chronic migraine is limited to a single trial of 59 
patients.(29)  The trial, comparing two months treatment with active treatment to treatment 
with a sham device, failed to show a difference in headache day reduction between the groups 
(reduction of 2 days per group).  An open-label extension phase suggested a significant 
difference emerges with a longer duration of treatment but further studies are needed to validate 
this.(30) 
Acute treatment of migraine <H4> 
There is no controlled data to support the use of transcutaneous vagal nerve stimulation with 
the gammaCore® device in the acute treatment of migraine.  Open-label data is, however, 
available on a total of 27 patients with episodic migraine (31) and 48 with high frequency or 
chronic migraine.(32)  In the episodic migraine cohort, a total of 80 attacks were treated and 
22% of attacks achieved pain freedom within two hours, a figure similar to that seen with 
Naproxen 500mg but below the 67% reported with Sumatriptan100mg. (31, 33, 34)  The series 
of high frequency and chronic migraine reported by Barbanti et al. (32) included 131 attacks 
treated over a 2-week period.  In this cohort, 23% were pain free at two hours.   
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Evidence for the use of invasive vagal nerve stimulation <H3> 
Invasive vagal nerve stimulation is carried out primarily for intractable epilepsy and involves 
the implantation of an electrode over the left vagus nerve.(35)  Following reports of pain relief 
in concurrent migraine attacks, some groups have used the implants for the treatment of 
intractable chronic migraine. 
Preventative treatment of chronic migraine<H4> 
The outcomes of invasive vagal nerve stimulation in chronic migraine are limited to three 
series.(36-38)  Mauskop reported on four patients treated with invasive vagal nerve stimulation, 
two of whom achieved substantial improvements.(36)  Hord et al. found four patients with 
migraine within their cohort of 27 epilepsy patients undergoing invasive vagal nerve 
stimulation.  All reported a decrease in migraine intensity and frequency, with one being 
rendered pain free.(38)  The final series by Cecchini and colleagues (2009) reported on four 
patients implanted for chronic migraine with two reporting a more than 50% reduction in 
headache frequency. 
Safety of vagal nerve stimulation <H3> 
Transcutaneous vagal nerve stimulation appears to be a safe treatment with no serious adverse 
events linked to the device recorded.  Using data from the above studies,(27, 31) the most 
common adverse events reported were facial muscle twitching, neck pain, rash or redness at 
the application site and worsening of the headache.  In sham-controlled studies,(27, 29) it was 
noted that similar proportions of active and control subjects reported adverse events and in fact, 
control subjects in the Silberstein et al. study (29) on chronic migraine prevention reported 
more adverse events of severe intensity than those in the active group. 
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The possible role of vagal nerve stimulation<H3> (Table 2) 
Available literature on transcutaneous vagal nerve stimulation using the gammaCore® device 
suggests that at present, it could be considered for the use of prevention of chronic cluster 
headache.  There is, as yet, insufficient evidence for the use of transcutaneous vagal nerve 
stimulation for acute or preventative treatment of migraine and the acute treatment of cluster 
headache. From current evidence, there is not a role for invasive vagal nerve stimulation in the 
treatment of primary headaches.   
Occipital nerve stimulation <H2> 
The occipital region is innervated by the greater, lesser and least occipital nerves.  The greater 
occipital nerve is a branch of the C2 spinal root and provides innervation to the occipito-parietal 
area around 6-8 cm wide ascending paramedially from the suboccipital region to the vertex.(39)  
There is an anatomical overlap between the cervical and trigeminal afferents from the level of 
the trigeminal nucleus caudalis to the level of C2.(8)  This overlap allows the stimulation of 
the occipital region to modulate pain in both trigeminal and cervical distributions.  Occipital 
nerve stimulation (ONS) involves a non-destructive surgical process whereby electrodes are 
placed subcutaneously in the occipital region at the level of C1 and then wired to an implantable 
pulse generator (IPG) in the chest, abdomen or occasionally buttocks.  Current batteries are 
rechargeable with a lifespan close to 10 years.  Patients are able to adjust their own stimulation 
intensity levels using a hand-held remote control.  Stimulation parameters of frequency, pulse 
width and voltage are adjusted to achieve continuous comfortable paraesthesia in the 
distribution of the greater occipital nerves.  The optimum settings for ONS are not yet defined 
and there is a wide variation in the stimulation settings used across centres. 
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Evidence for the use of occipital nerve stimulation <H3> 
ONS is most commonly used for chronic cluster and chronic migraine and so more extensive 
literature exists to support its use in these conditions.  As with other neurostimulation 
techniques, the majority of published data on the use of ONS for primary headaches consists 
of open-label case series.  However, randomised placebo-controlled trials have been conducted 
on the use of ONS in the prevention of chronic migraine.  Smaller open-label series exist for 
the use of ONS in SUNCT/SUNA and hemicrania continua.  Table 3 summarises the available 
published case studies on ONS in primary headache.  It is worth stressing the fact that there is 
no data to support the use of ONS in the acute treatment of any primary headache syndromes. 
Preventative treatment of chronic migraine<H4> 
The outcomes of the three randomised placebo-controlled trials on ONS in chronic migraine 
have been somewhat mixed.  The first trial conducted in 2009, the Precision Implantable 
Stimulator for Migraine (PRISM) study, reported on the outcomes of 125 subjects randomised 
to active or sham stimulation for three months.(40)  Although full results are not yet available, 
preliminary data failed to show a significant reduction in migraine days between treatment 
groups.  The second trial, the occipital nerve stimulation for the treatment of intractable chronic 
migraine headache (ONSTIM) study, published in 2011, was a randomised controlled study of 
61 subjects comparing active adjustable stimulation (28 patients), pre-set “sham” stimulation 
(16 patients) and standard medical treatment (17 patients).(41)  A positive clinical response 
(defined as a 50% reduction in headache days or greater than 3-point reduction in pain scores) 
was seen in 39% of the active adjustable stimulation group, 6% in the sham-stimulation group 
and 0% in the medical group.  The most recent study from Silberstein et al. published in 2012 
reported on 157 patients comparing active stimulation (105 patients) to sham stimulation (52 
subjects).(42)  The primary outcome measure of clinical responders (the proportion of patients 
achieving a 50% or more reduction in pain scores) showed no significant difference between 
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groups (17% vs. 14%).  However, significant differences between the groups were seen in the 
reduction of headache days (27% vs. 15%) and in the proportion of patients achieving a 30% 
or more reduction in pain scores (38% vs. 19%).  As the International Headache Society have 
issued clinical trial guidelines stating that, due to the intractable and highly disabling nature of 
chronic migraine, a 30% reduction in outcome measures should be considered as clinically 
relevant,(43) these findings can be interpreted as a positive outcome of ONS for chronic 
migraine.  A meta-analysis of the pooled data has found that ONS was associated with a 
reduction of 3 migraine days per month after three months of active treatment when compared 
to sham stimulation.(44)  Interestingly, comments are made in the same systemic review that 
the poor and incomplete reporting of data has hindered greater interpretation of results.  Open-
label data on ONS in chronic migraine is summarised in Table 3 (45)  and adverse event data 
that has been a cause for concern in some ONS series in Table 4. 
Preventative treatment of chronic cluster headache<H4> 
Although as of yet controlled data on the use of ONS in chronic cluster headache is not 
available, the available open-label data supports the potential efficacy of the treatment (Table 
3).(46)  Over 90 patients have been reported in the literature and a pooled analysis suggests a 
mean reduction of daily attack frequency of 67%.(47)  Numerous case series have been 
published (Table 3) and we will discuss some of the larger ones in more detail below.  
Individual case reports will not be explored. 
The first published cohort of ONS in chronic cluster headache was in 2007 and involved the 
prospective study of eight patients treated with unilateral ONS lead implantation ipsilateral to 
the side of pain.(48)  After a mean follow-up period of 15 months, five patients were considered 
to be clinical responders with a reduction of more than 50% in daily attack frequency.  In fact, 
all of these patients reported a more than 90% reduction in attack frequency and two remained 
pain-free for prolonged periods.  There was a delay of at least two months following implant 
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before clinical response emerged and attacks recurred or worsened within days to weeks of 
stimulation stopping - a feature that has been consistently reported in studies of ONS for 
primary headaches ever since.  The group also reported that two patients with initial relief of 
their cluster attacks went on to develop new attacks on the opposite side to the ONS electrode.  
This phenomenon has been confirmed by other series and has led to recommendations that 
bilateral leads are placed in all patients.  Although no serious adverse events were reported, 
lead migration and electrode displacement were observed (Table 4). 
Burns et al. reported on a cohort of 14 medically intractable chronic cluster headache patients 
undergoing bilateral ONS implants.(49, 50)  Following a median follow-up period of 18 
months, ten of the 14 patients reported an improvement.  Of those with benefit, three had a 
more than 90% reduction in attack frequency and a further three had a reduction of between 40 
and 60%.  As in the previous series by Magis et al.(48), a delay of weeks was seen until clinical 
response and attacks were seen to return within days when the devices were turned off.  
Adverse events reported included lead migration in nearly a third of patients, superficial 
infection, painful paraesthesia and neck stiffness (Table 4). 
In 2011, Fontaine and colleagues reported on their cohort of 13 chronic cluster headache 
patients undergoing ONS.(51)  After a mean follow-up period of 15 months, a reduction of 
68% was seen in mean attack frequency and a 50% improvement in attack frequency was seen 
in ten of the patients.   
Magis et al. have examined long-term efficacy in their cohort with a mean follow-up time of 
37 months.(52)  Of the 15 patients implanted, 14 went on to long-term follow-up (one implant 
was removed due to infection).  Eleven of the 14 patients reported a more than 90% reduction 
in attack frequency.  Again, the authors commented on side shifting of attacks when unilateral 
stimulation was employed and adverse events were similar to their previous report.  Other 
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groups looking at long-term outcome have also reported sustained efficacy over periods of 20-
33 months but patient numbers were very small; three in the series by Schwedt et al. and five 
in the series from Brewer et al.(53, 54). 
Preventative treatment of other TACs<H4> 
Published data on the use of ONS in SUNCT/SUNA is currently limited to a series of nine 
patients with median follow-up of 38 months.(55)  Authors report that four patients became 
pain free following treatment and all others had a more than 80% improvement in attack 
frequency.  As with ONS in chronic cluster headache, a time lag to clinical response was 
observed as was worsening of attacks within days to weeks of stimulation stopping.  A total of 
ten patients with hemicrania continua treated with ONS in an open-label fashion are currently 
reported in the literature.(53, 54, 56, 57)  All were treated with unilateral miniaturised 
stimulation devices no longer available for use.  Although outcome measures differ across the 
four cohorts, it appears that at least five were counted as clinical responders (Table 3).  There 
are no reports on the use of ONS in paroxysmal hemicrania as yet available in the literature. 
 
Safety of occipital nerve stimulation <H3> (Table 4) 
Major concerns have been voiced over the adverse event data collected from the controlled and 
open-label studies of ONS in primary headache, particularly hardware related events.  Adverse 
event data available in the literature is summarised in Table 4.(58-63)  Lead migration was 
reported in 24% of ONSTIM subjects,(41) 7% in the PRISM series (40) and in up to 19% of 
subjects in the extended phase of the Silberstein et al. cohort. (64)  Open-label series has 
reported lead migration rates between 4-53% with the series from Brewer et al. reporting the 
need for lead revision in 58% of patients.  A high rate of infection has also been reported in a 
number of series ranging from 4-29%.  Many of the complications reported in the ONS 
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literature are potentially serious and often require surgical intervention.  However, data is 
emerging that adverse event rates can be dramatically reduced if ONS implants are conducted 
by well-trained, highly experienced surgical teams specialising in ONS surgery.  A review of 
the adverse event data collected from the randomised study of Silberstein et al. showed that the 
incidence of surgery-related adverse events and the need for additional surgical procedures 
decreased with increased levels of surgical experience.  (65) 
The possible role of occipital nerve stimulation<H3> (Table 2) 
As with all invasive neuromodulation treatments, ONS should be reserved for those with highly 
intractable medical refractory guidelines that have failed to respond to all other treatments.  To 
stress this point, the European Headache Society has published clear guidelines on the use of 
invasive neurostimulation and this is summarised in Table 5.  From current data, ONS could 
be considered for the preventative treatment of refractory chronic migraine and cluster 
headaches (and possibly other TACs) once they have failed all available pharmacological 
input.  In order to minimise adverse events, patients should be assessed and treated in highly 
specialised units. 
 
Sphenopalatine ganglion stimulation <H2> 
The sphenopalatine ganglion (SPG) is an extracranial structure lying in the pterygopalatine 
fossa (PPF) containing both sympathetic and parasympathetic fibres.  The SPG has 
connections, both direct and indirect, to many centres considered important in nociception and 
the pathophysiology of cluster headache such as the trigeminovascular system, the superior 
salivatory nucleus and the hypothalamus.  Given the anatomy of the SPG, it has been 
investigated as a potential target in the treatment of cluster headache.  Sphenopalatine ganglion 
stimulation can be achieved using a Pulsante® device, which has controlled evidence for 
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efficacy in chronic cluster headache.  The Pulsante® device is a miniaturised implantable 
neurostimulator with integral lead and battery.  The lead is placed within the PPF using 
minimally invasive surgery with a trans-oral approach and the patient then controls the device 
using a handheld remote control. 
Evidence for the use of sphenopalatine ganglion stimulation <H3> 
Sphenopalatine ganglion stimulation has been developed for use in chronic cluster headache.  
Evidence is limited to one randomised control study although further studies are currently 
ongoing. 
Acute treatment of chronic cluster headache<H4> 
A randomised sham-controlled trial of 28 patients used the Pulsante® device to treat acute 
cluster attacks with either full, sub-perception or sham stimulation levels.(66)  Pain relief after 
15 minutes of SPG stimulation was seen in a significantly higher number of full-stimulation 
treated attacks (67%) than either sub-perception level (7%) or sham stimulation (7%).  After 
two months of treating acute attacks, only 31% of the full-stimulation group were still using 
medication to abort attacks compared to 77% in the sham stimulation group. 
Preventative treatment of chronic cluster headache<H4> 
During the above controlled trial, it was observed that subjects using the Pulsante® device 
began to report a reduction in attack frequency over time.  After the two month study period, 
43% of subjects using the full-stimulation device to treat attacks regularly reported a more than 
50% reduction in daily attack frequency suggesting that the device has a preventative 
effect.(66)  Further study into the efficacy and optimal stimulation settings of SPG stimulation 
as a preventative treatment for chronic cluster headache is ongoing. 
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Safety of sphenopalatine ganglion stimulation <H3> 
In the available study, 81% of subjects reported a transient sensory disturbance within the 
maxillary nerve distribution post-operatively but this resolved within three months in the 
majority of cases.(66)  Two patients reported lead migration and misplacement requiring 
surgical revision and one a post-operative infection requiring antibiotics. 
The possible role of sphenopalatine ganglion stimulation<H3> (Table 2) 
Guidelines for the use of SPG stimulation in chronic cluster headache were published by a 
group of headache experts in 2014.(67)  At present, the treatment should be considered as an 
acute treatment, with potential additional preventative effects, in those with medically 
intractable chronic cluster headache who have failed all available pharmacological therapies.  
The Pulsante® device may be particularly useful for those with contraindications to 
Sumatriptan or in those with a high frequency of daily attacks.   
CENTRAL NEUROSTIMULATION DEVICES<H1> 
Deep brain stimulation of the ventral tegmental area<H2> 
Functional neuroimaging studies on primary headache conditions have suggested that during 
acute cluster attacks there are changes in the posterior hypothalamic region in TACs that are 
not present in migraine.(12-15, 68)  Further work has shown that stimulation of the same area 
in cluster headache patients increases blood flow throughout areas of the central pain 
matrix.(69)  In 2001, Leone et al. used this functional imaging data evidence to implant deep 
brain electrodes in what was described as the posterior hypothalamic region in a patient with 
highly refractory chronic cluster headache.(70)  Detailed analysis of the anatomy of the region 
described in the literature and on imaging has suggested that the actual site of interest for deep 
brain stimulation (DBS) is the ventral tegmental area and not the posterior hypothalamus.(71)  
Stereotactic surgical techniques are used to place an electrode within the target area ipsilateral 
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to the side of headache.  The device is kept active at all times and patients have limited control 
over the settings. 
Evidence for the use of ventral tegmental area deep brain stimulation <H3> 
On the basis of the above functional neuroimaging studies, DBS is considered a possible 
treatment for TACs and not migraine.  Although there are now a number of open-label studies 
on the use of DBS for chronic cluster headache (Table 6) there is only one placebo-controlled 
trial available in the literature that, unfortunately, had deeply-flawed study design.(72)  Given 
the rarity of the TACs and the invasive nature of DBS surgery, it is highly unlikely that high 
quality controlled studies will ever be conducted in this area.  Deep brain stimulation has been 
proven ineffective in the acute treatment of cluster attacks.(73) 
Preventative treatment of chronic cluster headache<H4> 
There are now over 50 patients with DBS for chronic cluster headache published in the 
literature with an overall response rate (50% reduction in attack frequency or pain score) of 
71% (Table 6).  A summary of the available open-label series is given in Table 6 (72, 74-79) 
and the largest of these series are examined further below. 
Schoenen et al. implanted DBS leads into six patients with chronic cluster headache.(76)  After 
a mean follow-up of 14.5 months in four of the patients, two patients were pain free, one was 
having less than three attacks a month and one reported no effect.  One patient selected for 
treatment did not undergo implant due to a severe anxiety attack suffered during the operation.  
The only fatal adverse event recorded with DBS for headache occurred in this series with a 
patient dying post-operatively due to an intracerebral bleed along the lead.  This tragic outcome 
led to a review of the use of DBS and guidelines that stress that DBS should be considered only 
as a last resort in patients with no other treatment options.(80)  Bartsch et al. (74)published a 
series of six patients in 2008 with a follow-up of up to 17 months.  At follow-up, three patients 
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were almost pain free but one further patient who originally reported a more than 90% 
improvement in attack frequency lost efficacy over time so that after three months they no-
longer reported any benefit.  In 2011, both Franzini et al. (77) and Seijo et al.(78) each 
published a series of six patients undergoing DBS for chronic cluster headache.  In the cohort 
from Franzini, five patients were reported as being pain free after up to 22 months follow-up.  
In the Seijo series, all patients reported a more than 50% reduction in attack frequency after 
mean follow-up of 33 months with two being pain free.  This series commented on a number 
of clinically relevant observations such as the occurrence of a transient benefit or “stun period” 
for up to two weeks following implantation, a feature of the treatment that our group sees 
commonly but which is not widely discussed in the literature.  Again, a delay of weeks to 
months was observed before clinical benefit was observed and attacks were noted to return 
within days to weeks when stimulation was stopped.  In terms of adverse events, the group 
reports the most common complaints were of transient diplopia and dizziness related to 
changes in stimulation parameters.   
The largest open-label series of 16 patients in 2013 is also that with the longest follow-up 
period.  Leone et al.(79) reported that following a median follow-up of nine years, six remained 
pain free and a further six had converted to episodic cluster headache.  In five of the pain free 
patients, the stimulator had been switched off with long-term remission maintained.  Adverse 
events in the cohort included a post-operative seizure, infection (in four patients), electrode 
displacement (in two patients) and a non-symptomatic intraventricular haemorrhage was seen 
in one patient. 
Fontaine et al. performed a randomised sham-controlled crossover study on DBS for chronic 
cluster headache in 2010.(72)  In this study, 11 patients were enrolled to a protocol consisting 
of two crossover periods of either sham or active stimulation each lasting one month in duration 
followed by a one-year open-label extension period.  There was no difference in attack 
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frequency between active and sham groups at the end of the two months crossover period. 
However, by the end of the longer open-label phase, more than 50% of subjects reported a 
more than 50% reduction in attack frequency.  The negative outcome of the randomised part 
of the study is now considered to be due to poor study design with the cross-over periods far 
too short to account for the consistent delay to response seen in the open-label studies.  Adverse 
events in this cohort included infection of the system requiring removal of the hardware in one 
patient. 
Preventative treatment of SUNCT/SUNA<H4> 
The only other literature currently available on the use of ventral tegmental area DBS involve 
cases of SUNCT/SUNA.  In total there are three case reports (81-83) and a series of six patients 
with refractory SUNCT/SUNA treated with DBS.(84)  All three case reports were of successful 
treatment with all reporting a more than 90% improvement in attack frequency. In the case 
series, attack frequency reduced by a median of 79% and five out of six patients were 
considered clinical responders (Table 6). These data need to be interpreted with caution as the 
numbers reported are small and there is likely to be reporting bias. 
 
Safety of ventral tegmental area deep brain stimulation <H3> 
The death of a patient in the Schoenen et al. cohort from an intracerebral haemorrhage has led 
to concerns regards the safety of DBS in headache.(76)  Other reported adverse events include 
non-symptomatic intraventricular haemorrhage, infection sometimes necessitating removal of 
the DBS system and electrode displacement.  Adverse events from available cohorts are 
summarised in Table 6.  Due to the potential serious adverse events, guidelines for DBS patient 
selection have been produced emphasising that surgery should be offered as a last resort only 
in patients with TACs who have failed all other available treatments (Table 5).(80)  
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The possible role of ventral tegmental area deep brain stimulation<H3> (Table 2) 
On the basis of currently available evidence, DBS should be considered for medically 
intractable chronic cluster headache (and potentially other TACs) that have proven resistant to 
all other treatments, including other forms of neurostimulation.  Due to the risks of surgery, 
implants should only be undertaken in highly specialised units and guidelines state that patients 
should be managed by a multidisciplinary team including psychologists.(80)  
Transcranial magnetic stimulation<H2> 
It has been proposed that patients with migraine have a state of abnormal brain 
hyperexcitability and this theory is supported by transcranial magnetic stimulation studies.(7, 
9).  This hyperexcitable cortex is proposed to have a lower threshold for activation of cortical 
spreading depression (CSD), a process linked to the generation of migraine aura and activation 
of meningeal and trigeminal nociceptors.(10) Transcranial magnetic stimulation has been 
shown in animal studies to inhibit CSD and reduce cortical hyperexcitability by modulating 
levels of dopamine and glutamate.(9)  On the basis of animal studies, transcranial magnetic 
stimulation was investigated as a potential treatment for migraine with aura.  The SpringTMS® 
device, a single-pulse transcranial magnetic stimulator was designed specifically for migraine 
treatment.  The device applies a brief single magnetic pulse to the scalp and underlying cortex 
resulting in induced electrical field generation in the cortex, changes in neurotransmitter release 
and disturbance of CSD.  
Acute treatment of episodic migraine with and without aura<H4> 
The evidence for the use of the SpringTMS® device in acute migraine comes from a small 
sham-controlled study and post-marketing surveys.  The sham-controlled study involved 164 
migraine with aura patients using the device as an acute treatment for migraine attacks.(85)  
Active treatment was associated with a significantly higher rate of pain-freedom than sham 
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treatment at both two hours (39% vs. 22%) and twenty-four hours (29% vs. 16%) .  The 
therapeutic gain of transcranial magnetic stimulation for acute migraine treatment was 
calculated at 17%.  An open-label post-marketing survey included data on the acute treatment 
of migraine with and without aura in 190 patients who used the device for three months.(86)  
At the end of follow-up, 105 patients had discontinued the treatment mainly due to lack of 
efficacy, cost or convenience.  Of those completing the follow-up period, 62% were noted as 
reporting “some” reduction in migraine intensity and 59% “some” reduction in migraine 
duration.  
Preventative treatment of episodic or chronic migraine <H4> 
On the basis of currently available data, there is insufficient evidence to support the use of the 
SpringTMS® device in the preventative treatment of migraine. 
Safety of transcranial magnetic stimulation <H3> 
A safety review of published literature on the use of transcranial magnetic stimulation for 
migraine shows that the treatment is low-risk and well tolerated.(87)  The most commonly 
reported adverse events in the transcranial magnetic stimulator literature include dizziness and 
drowsiness during treatment.  In the sham-controlled trial from Lipton et al.,(85), prevalence 
of adverse events was low (14%) with no significant difference to the sham group (9%).  The 
events reported included worsening of headache and complaints of paraesthesia with treatment.  
Importantly, no subjects discontinued treatment due to adverse events. 
The possible role of transcranial magnetic stimulation<H3> (Table 2) 
Transcranial magnetic stimulation may have a role in the acute treatment of migraine with and 
without aura.  Given its efficacy as an acute treatment, the SpringTMS® stimulation device 
may be of potential benefit in patients who are at risk of overusing acute medications or in 
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whom acute medications are ineffective.  At present, transcranial magnetic stimulation does 
not appear effective in the prevention of migraine. 
 
MECHANISMS OF ACTION OF NEUROSTIMULATION<H1> 
Peripheral neurostimulation<H2> 
The mechanisms by which peripheral neurostimulation modulates an antinociceptive response 
is still poorly understood.  All of the peripheral nerves utilised for neurostimulation project 
either to the trigeminovascular system (occipital nerve, vagal nerve) or trigeminoautonomic 
system (sphenopalatine ganglion) which then project to brainstem centres such as the locus 
coeruleus and periaqueductal gray and further project to higher centres such as the thalamus 
(Fig 1).  This complex network is referred to as “the pain matrix” and functional neuroimaging 
suggests its major components include the primary and secondary somatosensory cortices, 
thalamus, anterior and posterior insula, anterior cingulate gyrus and prefrontal cortex.(69) This 
theory has been examined using functional neuroimaging of patients undergoing occipital 
nerve stimulation for headache (88-90)and vagal nerve stimulation for depression.(91)   
Matharu et al.(88) used positron emission tomography (PET) imaging to study eight patients 
with chronic migraine who had reported benefit to ONS.  Patients were studied in three states: 
pain-free and stimulation on, in pain with stimulation off and during partial stimulation with 
varying levels of pain.  Significant changes were observed in the regional cerebral blood flow 
in the dorsal rostral pons, anterior cingulate cortex and cuneus that were related to patient pain 
scores and changes in the anterior cingulate gyrus and left pulvinar regions correlated to 
paraesthesia scores. Magis and colleagues studied ten ONS-treated chronic cluster headache 
patients and compared them to 39 healthy volunteers using PET imaging.(90)  ONS patients 
were scanned at intervals varying between 0 and 30 months post-implant and with stimulation 
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on and off.  At time of imaging, three cluster patients were pain free and four more had a greater 
than 90% reduction in attack frequency.  Compared to controls, several areas of the pain matrix 
showed hyperactivity including the ipsilateral hypothalamus, midbrain and ipsilateral lower 
pons.  Activity in all of these areas normalised with ONS except for the hypothalamus.  The 
anterior cingulate cortex was a possible marker of efficacy as it was seen to be hyperactive in 
ONS responders compared to non-responders. 
Kovacs et al.(89)  investigated the potential mechanisms of action in ONS in healthy volunteer 
studying changes on functional MRI (fMRI) when stimulation was on or off.  Significant 
differences were seen in the activity of the hypothalamus, thalamus, orbitofrontal cortex, 
prefrontal cortex, periaqueductal gray, inferior parietal regions and cerebellum.  Suppression 
of activity was noted in the somatosensory areas, the amygdala, the hippocampus and primary 
motor cortex.   
The effects on fMRI of a sham-controlled transcutaneous vagal nerve stimulator designed for 
treatment of depression has been reported.(91)  The stimulation device was placed in the left 
external auditory meatus on the inner side of the tragus, an area known to receive innervation 
from the vagal nerve.  Following stimulation, a reduction in signal was seen in the 
parahippocampal gyrus, posterior cingulate cortex and right thalamus was observed.  Increased 
signal was observed in the anterior cingulate gyrus.  In the brainstem, a significant reduction 
was seen in signal from the locus coeruleus and solitary tract nucleus. 
In summary, simulation of the peripheral nerves is thought to modulate the afferent impulses 
travelling to the brainstem and higher centres resulting in long-term neuroplastic changes in 
various regions of the brain, including those outside of the regions stimulated.  The finding of 
persistent hyper-metabolism of the ipsilateral hypothalamus outside of an attack, even after 
successful ONS, may explain why attacks recur after stimulation is stopped. 
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Central neuromodulation<H2> 
Positron emission tomography studies have implicated the posterior hypothalamic region as 
being abnormally activated during attacks of cluster headache,(14) SUNCT/SUNA(15) and 
PH(12).  Further anatomical clarification at a later date revealed this area to be the ventral 
tegmental area and not posterior hypothalamus.(71)  This finding has not been replicated in 
migraine imaging.  The imaging findings seem to reinforce the concept of the hypothalamus as 
an important area in pain regulation and attack generation in TACs.  This theory led Leone and 
colleagues to implant a DBS lead in the area observed on PET imaging in 2000.(70)  Ten 
patients successfully treated with DBS for intractable chronic cluster headache underwent PET 
imaging to investigate the possible mechanisms behind DBS effect.  After ventral tegmental 
area stimulation activation was observed in the thalamus, somatosensory cortex, cuneus, 
anterior cingulate cortex and trigeminal nucleus and ganglion and deactivation in the middle 
temporal gyrus, posterior cingulate cortex and anterior insula.  All of these regions are 
structures involved in the neural circuits of the pain matrix discussed above and thus, similar 
to ONS, stimulation of the ventral tegmental area appears to result in long-term neuroplastic 
changes of descending pain processing pathways distant to the site of stimulation itself. 
During transcranial magnetic stimulation treatment for migraine a magnetic field is applied to 
the scalp.  This field penetrates the scalp and induces a current in the underlying cortex.  The 
induced electric field alters the membrane potentials, resulting in either depolarisation or 
repolarisation of a neuronal population.  In the treatment of migraine with aura, this current is 
hypothesised to disrupt CSD as has been observed in animal studies.(92) 
 
CONCLUSIONS <H1> 
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Primary headache disorders are among the most commonly encountered neurological 
disorders, yet effective evidence based treatments, particularly the chronic forms, are lacking.  
With low satisfaction rates for traditional preventative medications due to tolerability and 
efficacy there is a growing demand for new treatment options for headache patients.  
Neurostimulation is emerging as a promising treatment option modality particularly for 
medically intractable chronic migraine and chronic TACs or those with contraindications to 
other medication.  Open-label data is providing evidence that they can improve quality of life 
in highly disabled chronic headache patients and they can offer hope to many more.  However, 
the quality of current evidence is poor and the ultimate confirmation of any new therapeutic 
modalities should come from randomised controlled trials.  This poses a problem with 
neurostimulation as the paraesthesia created during treatment with many of these devices 
creates limits on what would constitute adequate placebo.  Another issue with sham stimulation 
is that the level of current below which clinical effect is lost has not been investigated.  It is 
therefore possible that previous sham studies have been using active placebo rather than 
control, a situation that complicates interpretation of the data.  From available efficacy data, 
neurostimulation treatments appear to have efficacy similar or below that of available 
preventative treatments.  However, their adverse event and tolerability data (especially in non-
invasive devices) is far superior to current medications.  At present, the place for 
neurostimulation seems to lie in two clear patient groups.  The first is those with medically 
intractable chronic headaches where the cost and risk of treatment may be offset by the 
potential benefit in those with otherwise limited options.  The second group is those with 
contraindications or intolerance to medications.  This is a situation where the non-invasive 
devices may show major potential benefit especially if they can provide effective acute relief.  
In the future, if robust evidence can be generated, neurostimulation will likely take a prominent 
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place in the treatment regimes of headache. However, until such a time, patients must be 
selected carefully in line with current guidelines. 
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 Migraine Cluster headache Paroxysmal 
hemicrania 
SUNCT/SUNA Hemicrania 
continua 
Frequency in 
general population 
15% (2% chronic) 0.2% Rare Rare Rare 
Sex Ratio Female>male Male>women Female=Male Male>Female Female>Male 
Pain:      
Description 
 
Throbbing, aching, 
squeezing 
 
Stabbing, boring 
 
Stabbing, boring, 
throbbing 
 
Sharp, stabbing, 
neuralgiform 
 
Background pain: 
dull, heavy 
Exacerbations: 
throbbing, aching, 
squeezing 
Severity 
 
Moderate to severe 
 
Severe, excruciating 
 
Severe, excruciating 
 
Severe, excruciating 
 
Mild to moderate 
background pain 
with severe 
exacerbations 
 
Laterality Unilateral or bilateral Unilateral Unilateral Unilateral Unilateral 
Attack Frequency Variable 1 to 8 attacks a day 5-40 attacks a day 3-200 attacks a day Continuous pain 
Attack duration Hours 15-180 mins 2-30 mins 5-240 sec Continuous pain 
Periodicity - Circadian and 
circannual ++ 
Circadian and 
circannual +/- 
- - 
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Autonomic 
features* 
Sometimes, mild Yes Yes  Yes Yes, with 
exacerbations 
Migrainous 
features** 
Yes Yes, may be mild Yes, may be mild Rare Yes 
Triggers      
Alcohol Yes Yes No No No 
Cutaneous touch No No No Yes No 
Indometacin 
response 
None None Complete resolution None Complete resolution 
Abortive treatment Oral triptan, NSAID Subcutaneous 
Sumatriptan, 
Oxygen 
Nil Nil Nil 
First-line 
prophylactic 
Beta-Blockers, 
tricyclic 
antidepressant, 
topiramate 
Verapamil, lithium, 
topiramate 
Indometacin Lamotrigine, 
oxcarbazepine 
Indometacin 
NSAID, non-steroidal anti-inflammatory drugs; SUNA, short-lasting unilateral neuralgiform headache attacks with autonomic features; 
SUNCT, short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing;  
* Autonomic features: One or more of ptosis, lacrimation, conjunctival injection, facial redness/sweating, eyelid/facial swelling, nasal stuffiness, rhinorrhea 
** Migrainous features: One or more of nausea and/or vomiting, photophobia, phonophobia 
 
Table 1. Clinical features of the primary headache disorders   
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 Supraorbital 
Stimulation 
 
Vagal Nerve 
Stimulation 
 
Transcranial 
Magnetic 
Stimulation 
Occipital Nerve 
Stimulation 
Sphenopalatine 
Ganglion 
Stimulation 
Deep Brain 
Stimulation 
Device Name Cefaly gammaCore Spring TMS  Pulsante  
Treatment Use       
Acute migraine 
attacks 
X √ √ (with and without 
aura) 
X X X 
Prevention of 
episodic migraine 
√ X X X X X 
Prevention of 
chronic migraine 
X X X √ X X 
Acute cluster 
attacks 
X X X X √ X 
Prevention of 
episodic cluster 
headache 
X √* X X X X 
Prevention of 
chronic cluster 
headache 
X √ X √ √ (studies on-going) √ 
Other TACs X X X √ 
(prevention of chronic 
intractable TACs) 
X √ 
(prevention of chronic 
intractable TACs) 
TACs, Trigeminal Autonomic Cephalalgias  
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*Usefulness may be dictated by length of episodic cluster bout, if bout lasts less than 3 months may be difficult to assess as treatment may take this long to have clear effect 
Table 2: Summary table of the possible roles of neurostimulation in primary headache disorders   
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Trial (first author, year) Patients (n) Average follow-up (months) Response rate  
(proportion reporting at least 
50% reduction in attack 
frequency) 
Supraorbital nerve stimulation (+/- ONS) for chronic migraine 
Reed et al.(22)  7 17 100% 
Hann and Sharan(23)  14 31 71% *  
TOTAL 21 16 86% 
 
ONS for chronic migraine 
Saper et al.(41) 75 3 months 39% **  
Silberstein et al.(42)  
[Extended follow up, Dodick et 
al.(64) ] 
157 
[157] 
3 months 
[12 months] 
17%  
[60%] 
Brewer et al.(53) 12 34 months 42% 
Lipton et al.(40) 125 3 months N/A (-6 days week active group vs. -4 
days week sham group, p=0.29) 
Mueller et al.(45)  3 7 month 100% *** 
Paemeleire et al.(62) 8 24 month 71%**** 
TOTAL 380 12 month 42% 
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[53%] 
 
ONS for chronic cluster headache 
Magis et al.(48, 52) 14 37 86% 
Schwedt et al.(54) 3 19 33% 
Brewer et al.(53) 5 41 80% 
Burns et al.(49, 50) 14 18 36% 
Fontaine et al.(51) 13 15 77% 
Mueller et al. (45) 24 22 month 88% *** 
Mueller et al.(46) 10 12 month 90% *** 
TOTAL 83 23 month 62% 
 
ONS for SUNCT/SUNA 
Lambru et al.(55)  9 38 month 89% 
 
ONS for hemicrania continua 
Burns et al.(56)  6 14 67% 
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ONS, occipital nerve stimulation; SUNCT, short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing; SUNA, short-lasting 
unilateral neuralgiform headache attacks with autonomic features  
*Clinical response defined as least 50% reduction in headache severity 
**Clinical response defined as least 50% reduction in monthly headache days or greater than 3 point reduction verbal rating scale 
*** Definition of response not given/unclear, not included in response rate total 
**** response defined by least 3 point reduction verbal rating scale 
[ ] data from extended follow-up of the original Silberstein (2012) series 
 
Table 3: Evidence from published case series for occipital nerve stimulation in primary headache conditions  
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Author Number 
patients 
Duration 
follow-up 
(mean) 
Hardware related 
complications 
Surgical 
action 
required 
Biological related 
complications 
Surgical 
action 
required 
Stimulation related 
complications 
Surgical 
action 
required 
Weiner and 
Reed (58) 
13 2.4 years Migration 
 
1 (8%) 1 (8%) Infection 
 
1 (8%) 1 (8%)    
Popeney 
and Alo 
(59) 
25 18.3 
months 
Migration 
Re-implantation 
post infection 
9 (36%) 
1 (4%) 
0 (36%) 
1 (4%) 
Infection 
 
1 (4%) 1 (4%)    
Fontaine et 
al. (51) 
20 6 months-
4 years 
(no mean 
given) 
Migration 
Explantation 
(headache free) 
Battery failure 
7 (35%) 
1 (5%) 
 
1 (5%) 
7 (35%) 
1 (5%) 
 
1 (5%) 
Infection 
 
2 (10%) 
 
1 (5%)    
Johnstone 
and 
Sundaraj 
(60) 
7 25 months Re-implantation 
post infection 
2 (29%) 2 (29%) Infection 
 
2 (29%) 2 (29%)    
Slavin et al. 
(61) 
10 22 months Migration 
Explantation 
(headache free) 
1 (10%) 
1 (10%) 
1 (10%) 
1 (10%) 
Infection 
Neck pain 
 
1 (10%) 
1 (10%) 
1 (10%) 
1 (10%) 
   
Magis et al. 
(93) 
8 15.1 
months 
Migration 
Lead fracture/ 
displacement 
Battery failure 
1 (13%) 
1 (13%) 
 
4 (50%) 
0 
0 
 
4 (50%) 
IPG/Lead/Wou
nd pain 
 
2 (25%) 0 Undesirable 
changes in 
stimulation 
 
1 (13%) 1 (13%) 
Schwedt et 
al. (54) 
15 3 year Migration 
Battery failure 
 
8 (53%) 
5 (33%) 
N/A 
N/A 
IPG, Lead or 
Wound pain 
Neck stiffness 
12 (80%) 
 
5 (33%) 
N/A 
 
N/A 
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Wound site 
complications 
 
4 (27%) 
 
N/A 
Burns et al. 
(50) 
14 17.5 
months 
Migration 
Lead fracture/ 
displacement 
Explantation 
(lack efficacy) 
Battery failure 
Additional 
electrode 
 
3 (21%) 
2 (14%) 
 
1 (7%) 
 
8 (57%) 
1 (7%) 
3 (21%) 
2 (14%) 
 
1 (7%) 
 
6 (57%) 
1 (7%) 
Infection 
IPG, Lead or 
Wound pain 
Neck stiffness 
Wound site 
complications 
 
3 (21%) 
4 (29%) 
 
1 (7%) 
1 (7%) 
0 
0 
 
0 
0 
Undesirable 
changes in 
stimulation 
 
4 (29%) 0 
Lipton et 
al. (40) 
[Data from 
(Sharan et 
al.(65)] 
125 12 week Migration 
 
7% N/A Infection 
IPG, Lead or 
Wound pain 
15% 
8% 
N/A 
N/A 
   
Paemeleire 
et al. (62) 
44 36 months Migration 
Lead fracture/ 
displacement 
 
2 (5%) 
9 (21%) 
2 (5%) 
9 (21%) 
Infection 
IPG, Lead or 
Wound pain 
 
2 (5%) 
3 (7%) 
0 
3 (7%) 
   
Saper et al. 
(41) 
 
 
51 3 month Migration 
Lead fracture 
 
12 (24%) 
1 (2%) 
N/A 
N/A 
Infection 
IPG, Lead or 
Wound pain 
Neck stiffness 
Wound site 
complication 
12 (24%) 
5 (10%) 
 
2 (4%) 
4 (8%) 
N/A 
N/A 
 
N/A 
N/A 
Undesirable 
changes in 
stimulation 
3 
(6%) 
  
 
 
N/A 
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Fontaine et 
al. (51) 
13 14.6 
months 
   Infection 
Wound site 
complication 
1 (8%) 
1 (8%) 
1 (8%) 
1 (8%) 
Undesirable 
changes in 
stimulation 
1 (8%) 0 
Magis et al. 
(52) 
15 36.8 
months 
Migration 
Battery failure 
 
1 (7%) 
9 (60%) 
1(7%) 
9 (60%) 
Infection 
IPG, Lead or 
Wound pain 
3 (20%) 
5 (33%) 
3 (20%) 
0 
Undesirable 
changes in 
stimulation 
3 (20%) 1 (7%) 
Brewer et 
al. (53) 
26 8.5 years Migration 
Explantation 
(headache free 
x2, lack efficacy 
x3) 
Battery failure 
Lead revisions 
1 (4%) 
5 (19%) 
 
 
1 (4%) 
15 (58%) 
0 
5 (19%) 
 
 
0 
15 (58%) 
Infection 
 
1 (4%) 1 (4%) 
 
   
Silberstein 
et al. (42)  
 
 
157 12 weeks Migration 
Lead fracture/ 
displacement 
Erosion 
 
20 (13%) 
2 (1%) 
 
7 (5%) 
N/A 
N/A 
 
N/A 
Infection  
IPG, Lead or 
Wound pain 
Wound site 
complication 
Allergy to 
surgical 
material 
7 (5%) 
23 (15%) 
 
4 (3%) 
 
4 (3%) 
N/A 
N/A 
 
N/A 
 
N/A 
Undesirable 
changes in 
stimulation 
 
9 (6%) N/A 
Palmisani 
et al. (63) 
23 36 months Migration 
Fracture 
Erosion 
(all with 
associated 
infection) 
 3 (13%) 
2 (9%) 
3 (13%) 
 
 
 
Infection  2 (9%) Undesirable 
changes in 
stimulation 
 
 2 (9%) 
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Explantation 
(lack efficacy) 
4 (17%) 
Dodick et 
al.(64)  
157 52 weeks Migration 
Lead fracture/ 
displacement 
Skin erosion 
Battery failure 
 
29 (19%) 
7 (4%) 
 
8 (5%) 
8 (5%) 
27 (17%) 
7 (4%) 
 
7 (4%) 
7 (4%) 
Infection 
IPG, Lead or 
Wound pain 
Wound site 
complication 
Allergy to 
surgical 
material 
 
11 (7%) 
38 (24%) 
 
6 (3%) 
 
5 (3%) 
6 (4%) 
12 (8%) 
 
1 (1%) 
 
2 (1%) 
Undesirable 
changes in 
stimulation 
 
17 (11%) 8 (5%) 
 
 
 
 
IPG, Implantable pulse generator; N/A, Data not available from paper 
Table 4: Adverse reactions reported in published occipital nerve stimulation series.
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 Patient must meet the International Headache Society criteria for chronic 
migraine or trigeminal autonomic cephalalgia  
 For chronic cluster headache, patients should have had daily or near daily 
attacks for at least two years prior to stimulation 
 Patients should have been under the care of a headache specialist team for 
at least one year 
 All reasonable drugs must have been tried at the correct doses and for 
sufficient durations unless contraindicated  
 All patients should have a psychological assessment prior to surgery  
 All co-existent conditions should be identified and treated where possible 
prior to surgery (e.g. depression, medication overuse) 
 Patients (and doctors) must have a realistic expectation of the surgical 
outcome 
 Patients should be followed up by the headache specialist team for at least 
one year 
 Prospective headache diaries recording headache attack frequency, 
severity and duration as well as analgesia intake must be kept  
 Appropriate quality of life measures, disability scores and self-assessments 
must be kept by the patient prior and post-operatively 
 Where possible the neurostimulator should only be switched off for 
efficacy assessment, ideally in a double-blind fashion. 
 A clear record of adverse events is kept 
 
Table 5.  Criteria for the use of invasive neurostimulation in primary headache 
[adapted from Martelletti et al.(80) and Leone et al.(94)]
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Trial (first 
author, year) 
Patients 
(n) 
Average 
follow-up 
(months) 
Response rate 
(Proportion 
reporting least 
50% reduction 
attack frequency) 
Adverse Events (n) 
DBS for chronic cluster headache  
Schoenen et al. 
(76) 
4  (6 
implante
d) 
15 months 75% Fatal intracerebral 
haemorrhage (1), 
severe anxiety attack 
at time of implant (1) 
Franzini et al. 
(77) 
5 12 month 100% pain free  
Seijo et al.(78) 5 33 months 100% Meiosis (3), Cable 
rupture (2) 
Bartsch et al. 
(74) 
6 17 month 50% Cable revision (1) 
Fontaine et al. 
(72) 
11 12 month  
 
55%  Infection (1) 
Leone et al. 
(79)  
17 108 month 70% Electrode migration 
(2), infection (4), 
intraventricular 
haemorrhage (1), 
seizure (1) 
Starr et al. (75) 4 12 month 50% Transient ischaemic 
attack (1) 
TOTAL 52 30 month 71%  
 
DBS for SUNCT/SUNA  
Lyons et al. 
(83) 
1 12 months 100% Nil 
Miller et al.  
(84) 
6 10 months 83% Nil 
Bartsch  
et al. (82) 
1 15 month 100% Nil 
Leone et al. 
(81) 
1 10 month 100%  Nil 
Pg 54 
 
 
DBS, deep brain stimulation; SUNA, short-lasting unilateral neuralgiform headache attacks with 
autonomic features; SUNCT, short-lasting unilateral neuralgiform headache attacks with conjunctival 
injection and tearing  
Table 6: Available evidence from published case series for ventral tegmental area deep 
brain stimulation in primary TACs 
  
TOTAL 9 12 months 96%  
Pg 55 
 
 
--- Vagal nerve afferents feed into the TNC via the nucleus tractus solitarisand the locus coerueus 
LC, Locus ceruleus;  NRM, Nucleus raphe magnus;; PAG, Periaqueductal gray; SPG, Sphenopalatine 
ganglion; ; SSN, superior salivatory nucleus; TNC, Trigeminal nucleus caudalis; V1, First branch of 
the trigeminal nerve 
 
Figure 1: Schematic of headache pain pathways and the targets for neurostimulation  
 
